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Understanding effects of chronic nicotine requires identifying the neurons and synapses whose responses to nicotine itself, and to
endogenous acetylcholine, are alteredby continued exposure to thedrug. To address this problem,wedevelopedmicewhose4nicotinic
receptor subunits are replaced by normally functioning fluorescently tagged subunits, providing quantitative studies of receptor regu-
lation atmicrometer resolution. Chronic nicotine increased4 fluorescence in several regions; among these,midbrain andhippocampus
were assessed functionally. Although themidbrain dopaminergic system dominates reward pathways, chronic nicotine does not change
4* receptor levels in dopaminergic neurons of ventral tegmental area (VTA) or substantia nigra pars compacta. Instead, upregulated,
functional4* receptors localize to the GABAergic neurons of the VTA and substantia nigra pars reticulata. In consequence, GABAergic
neurons from chronically nicotine-treated mice have a higher basal firing rate and respond more strongly to nicotine; because of the
resulting increased inhibition, dopaminergic neurons have lower basal firing and decreased response to nicotine. In hippocampus,
chronic exposure to nicotine also increases4* fluorescence on glutamatergic axons of themedial perforant path. In hippocampal slices
from chronically treated animals, acute exposure to nicotine during tetanic stimuli enhances induction of long-term potentiation in the
medial perforant path, showing that the upregulated 4* receptors in this pathway are also functional. The pattern of cell-specific
upregulation of functional 4* receptors therefore provides a possible explanation for two effects of chronic nicotine: sensitization of
synaptic transmission in forebrain and tolerance of dopaminergic neuron firing in midbrain.
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Introduction
Drugs of abuse induce changes such as tolerance, dependence,
sensitization, and pleasure-seeking behavior. Chronic exposure
to the drug may lead to changed levels and/or responsiveness of
drug receptors themselves. For example, desensitization, down-
regulation, and recycling of opioid receptors are thought to play
key roles in opioid addiction (Waldhoer et al., 2004).
Chronic nicotine induces at least two phenomena that are
challenging to explain in terms of changed receptor levels. The
first is sensitization, both locomotor (Ksir et al., 1985; de Rover et
al., 2004) and cognitive (Rezvani and Levin, 2001; Dani and Ber-
trand, 2007). In the human context, cognitive sensitization is
epitomized by smokers’ reports that they think better when they
smoke; this anecdotal observation is confirmed by data that
smokers who smoke nicotine cigarettes (but not nicotine-free
cigarettes) display certain cognitive enhancements (Rusted and
Warburton, 1992; Rusted et al., 1995). In the context of our stud-
ies on mice, rodents show more contextual fear conditioning if,
1 d after withdrawal from chronic nicotine, they receive an acute
nicotine dose (Davis et al., 2005); also chronic nicotine produces
better spatial working memory performance in the radial arm
maze (Levin et al., 1990, 1996). The second phenomenon is tol-
erance to other effects such as reward; for instance, repeated nic-
otine treatment or nicotine self-administration results in chronic
tolerance of mesolimbic dopamine release, which is closely asso-
ciated with drug reward (Cadoni and Di Chiara, 2000; Di Chiara,
2000; Rahman et al., 2004).
Classical studies show that chronic nicotine exposure in-
creases nicotinic acetylcholine receptor levels, but the increases
differ among receptor subtypes and even vary among brain re-
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gions for the same subtype (Marks et al., 1983, 2004; Schwartz
and Kellar, 1983; Pauly et al., 1996; Nguyen et al., 2004; McCal-
lum et al., 2006). Data on isolated cells expressing nicotinic re-
ceptors also show that the upregulated receptors retain function
and suggest that this upregulation arises primarily because more
nicotinic receptors are assembled or stabilized in an easily acti-
vated state (Nashmi et al., 2003; Darsow et al., 2005; Kuryatov et
al., 2005; Sallette et al., 2005; Vallejo et al., 2005). These changes
may underlie mechanisms of sensitization. However, upregula-
tion clearly disagrees with expectations that tolerance to nicotine
is caused by fewer, or less functional, receptors. However, al-
though the weight of evidence suggests that the upregulated re-
ceptors retain function (Nashmi et al., 2003; Nguyen et al., 2004;
Darsow et al., 2005; Kuryatov et al., 2005; Sallette et al., 2005;
Vallejo et al., 2005), it is still a viable hypothesis that most of the
numerically upregulated receptors are actually desensitized, so
that the upregulation would be masked or distorted by an overall
decrease in sensitivity (Dani and Heinemann, 1996; Gentry and
Lukas, 2002). The desensitization theory nicely explains toler-
ance, but it cannot directly explain sensitization.
This set of paradoxes, which we term the “upregulation di-
lemma,” has led some researchers to suggest that nicotinic recep-
tor upregulation is an epiphenomenon during chronic exposure
to nicotine. Other signal transduction mechanisms, especially
arising from Ca2 influx through activated nicotinic acetylcho-
line receptors (nAChRs), apparently lead to adaptations in other
proteins in addition to nAChRs (Chang and Berg, 2001; Ferrari et
al., 2002; Brunzell et al., 2003; Marrero et al., 2004; Yeom et al.,
2005; Marttila et al., 2006; Yamazaki et al., 2006b; Fornari et al.,
2007). These adaptations, downstream from the receptors, could
govern nicotine addiction at the cellular and circuit level (Koob et
al., 2004; Laviolette and van der Kooy, 2004).
To assess the importance of receptor upregulation in the
changes provoked by chronic nicotine, we askedwhether upregu-
lation can provide an explanation for chronic nicotine effects,
both in the areas in forebrain thought to govern some simple
aspects of cognition, as well as in the areas inmidbrain thought to
govern tolerance and reward. Tomonitor receptor changes, both
numerically and functionally at a cellular level, we used an ap-
proach based on fluorescent receptors in knock-in mice. We
studied receptors containing the 4 nicotinic receptor subunit
(4* receptors, primarily 42* receptors), because (1) these are
among the most nicotine-sensitive subtypes (Luetje and Patrick,
1991), (2) these are also among those upregulated by chronic
nicotine (Flores et al., 1992; McCallum et al., 2006), and (3)
nicotine activation of these receptors is both necessary and suffi-
cient for tolerance, sensitization, and reward behavior (Picciotto
et al., 1998; Tapper et al., 2004; Maskos et al., 2005).
Materials andMethods
Mice. All experiments were conducted in accordance with the guidelines
for care and use of animals provided by the National Institutes of Health,
and protocols were approved by the Institutional Animal Care and Use
Committee at the California Institute of Technology or the University of
Colorado, Boulder.Mouse strains used in this study included4YFP (see
below), 4(Leu9Ala) (Tapper et al., 2004), 4 knock-out (KO) (Ross et
al., 2000), andGAT1-green fluorescent protein (GFP) (Chiu et al., 2002).
Mice were kept on a standard 12 h light/dark cycle at 22°C and given food
and water ad libitum. The 4YFP mice had a mixed Sv129/C57BL/6
background with one or more generations backcrossed to C57BL/6.
Thus, all tissues studied were derived from mice with a mixed Sv129/
C57BL/6 background, except that the slice experiments used inbred
C57BL/6 mice.
4YFP mouse construction. The strategy used to generate the 4YFP
line adapts the procedures used to generate the previous Leu9Ser line
(Labarca et al., 2001; Tapper et al., 2004; Fonck et al., 2005) (see Fig.
1A–D). From previous work, we have in hand a 129/SvJ 4 genomic
clone containing exon 5 and exon 6 with the L9S mutation in the vector
pKO Scrambler V907 (15.2 kb in length; Lexicon Genetics, The Wood-
lands, TX). A neomycin resistance cassette with a phosphoglycerate ki-
nase promoter and polyadenylation signal flanked by loxP sites is present
166 bp downstream from exon 5 for positive selection. The diphtheria
toxin A chain gene with an RNA polymerase II promoter has also been
added to provide negative selection for random insertion.
A 4.1 kb cassette containing exon 5 and the L9S mutation was re-
moved from the pKO vector via digestion with SpeI and inserted into
pBlueScript for modification (7.2 kb total length). The L9S mutation
was replaced with its wild-type (WT) codon by replacing an AvrII and
SacI fragment (5.7 kb) by enzyme digestion and ligation from a WT 4
genomic clone in Bluescript. According to our previous work, we found
that the optimal insertion site for yellow fluorescent protein (YFP) was a
BstEII site in the M3–M4 cytoplasmic loop of 4 (Nashmi et al., 2003).
There were two BstEII sites in the 4.1 kb SpeI fragment inserted in pBlue-
Script, however. Therefore, a partial digestionwas performedwithBstEII
enzyme so that only one of the two sites was cut. YFP was cut from the
previously published 4YFP cDNA construct with BstEII (Nashmi et al.,
2003), and then ligated to the 4.1 kb cassette in pBlueScript. The YFP
insert also contained an immediately upstream hemagglutinin (HA)-
epitope tag. Restriction analysis with BsrGI and sequencing confirmed
correct insertion orientation. The 4.1 kb exon 5 cassette was then re-
moved by digestion with SpeI and ligated back into the 4(L9S)
knock-in construct, thus replacing the L9S mutation with the WT
L9codon and inserting the YFP sequence. Clones were screened for
correct orientation with restriction analysis using NsiI enzyme and se-
quencing. The 4YFP knock-in construct (15.9 kb) was linearized with
NotI, chloroform/phenol extracted, precipitated in ethanol-ammonium
acetate at 20°C, and resuspended in sterile water in preparation for
introduction into mouse embryonic stem cells (ES cells).
CJ7 mouse ES cells were electroporated with 25 g of linearized
knock-in construct. Four rounds of electroporation were performed us-
ing 7  107 ES cells per electroporation. After electroporation, each
group of cells was plated on 10 cm dishes containing single layers of
mitotically inactivated mouse primary fibroblasts. To select for recom-
binant clones, geneticin (G418) (180 g/ml) was applied to ES cells 24 h
after plating. Cell death was apparent 3 d after treatment. After 8 d of
G418 treatment, 384 resistant colonies were picked and plated onto 96-
well plates, grown for 72 h, trypsinized, and then split onto duplicate
plates, one for freezing the other for screening. Correct recombinant
colonies were screened for the presence of the neo cassette and YFP insert
by a combination of PCR and automated sequence analysis. DNA for
PCR and sequencing was isolated by applying lysis buffer (10 mM Tris,
pH 7.5, 10 mM EDTA, 10 mMNaCl, 1% SDS, and 1 mg/ml proteinase K)
to cells and incubating overnight at 60°C followed by ethanol precipita-
tion. To confirm the correct position of the homologous recombination
of the targeting construct within the genome and the insertion of YFP and
neo cassette, ES cells were screened by PCR and sequencing. Two separate
sets of PCRs were performed. One PCR included the forward primer
(SEQS), 5-GACCAACTGGACTTCTGGGAAAGTG-3, and the reverse
primer (SEQYFPAS), 5-CTGTTGTAGTTGTACTCCAGCTTGTG-3.
The second PCR included the forward primer (SEQYFPS), 5-CACA-
AGCTGGAGTACAACTACAAC-3, and the reverse primer (S10L3AS),
5-CACTCCTACTGGTCTAGAGAGATG-3. Karyotype analysis was used
to assess chromosome number. Two positive clones with the highest per-
centage of proper chromosome number (90%) were selected for the subse-
quent round of electroporation.
Previous work with the Leu9Ser mice has indicated that the presence
of the neo cassette reduces expression of the target gene by approximately
fourfold. To maximize expression of the mutated gene, we deleted the
neo cassette. This was done by electroporating two clones of the neo-
intact 4YFP ES cells with cytomegalovirus-Cre plasmid, leaving only a
single 34 bp loxP. Electroporation was performed as described above.
Cells were plated at a low density (600 cells/plate) onto 10 cm dishes
containing single layers of mitotically inactivated mouse primary fibro-
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blasts. A total of 178 colonies were picked and plated onto two 96-well
plates, grown for 48 h, trypsinized, and split onto triplicate 96-well plates,
one for freezing and two for screening. Clones were initially selected for
neo cassette deletion by G418 (180 g/ml) treatment. G418-sensitive
clones were then further screened using a combination of PCR and auto-
mated sequencing. Primers were designed to anneal to a DNA sequence
upstream of the 5 loxP site while inside the YFP sequence (SEQYFPS),
5-CACAAGCTGGAGTACAACTACAAC-3, and downstream of the 3
loxP site (SwaI/loxPAS), 5-CAGGTGTTAGAATCATAGGGCTAG-3. All
neo-deleted clones were sequenced to confirm the presence of the YFPmu-
tation and deletion of the neo cassette. Karyotype analysis was used to verify
normal chromosomenumber.Twoneo-deleted4YFPcloneswere injected
into C57BL/6 blastocysts, and chimeras were established. Chimeras were
matedwithwild-type animals and germline transmissionwas established as as-
sessed by PCR analysis of tail DNA and sequence analysis. Primers used for
genotyping included the following: A4XFPF, 5-CAACCGCATGGACACAG-
CAGTCGAGAC-3; A4XFPM, 5-GCACAAGCTGGAGTACAACTACAA-
CAGC-3; A4XFP2R, 5-CTCAGTCAGGGAAGCAGCTCCATCTTG-3.
RT-PCR. Total RNA was extracted from combined fresh frozen thal-
amus and ventralmidbrain tissue fromheterozygous (Het) andWT4YFP
mice (RNeasy Protect number 74124; Qiagen, Valencia, CA). The first-
strand cDNAwas synthesized using SuperScript II reverse transcriptase (In-
vitrogen, Carlsbad, CA) with the specific primer A4RTPCRAS, 5-
GATCATACCAGCCAACCATGGAG-3. PCR amplification of 4YFP
nAChRwas done using the following primers: A4XFPF, 5-CAACCGCAT-
GGACACAGCAGTCGAGAC-3; A4XFPM, 5-GCACAAGCTGGAGTA-
CAACTACAACAGC-3; A4RTPCRAS, 5-GATCATACCAGCCAACCA-
TGGAG-3.
Acetylcholine-stimulated 86Rb efflux. Nicotine-stimulated 86Rb ef-
flux from thalamic and cortical synaptosomes of WT, Het, and homozy-
gous (Hom) 4YFP mice was measured as described previously (Marks
et al., 1999). Cortex and thalamus (excluding habenula) were dissected
from adult mice killed by cervical dislocation. Tissue was homogenized
by hand in 1ml of ice-cold 0.32 M sucrose buffered to pH 7.5 withHEPES
using a glass/Teflon tissue grinder. After homogenization, the grinder
was rinsed three times with 0.5 ml of buffered sucrose solution. A crude
synaptosomal pellet was obtained by centrifugation at 12,000 g for 20
min. After removal of the sucrose, each pellet was resuspended in 0.35ml
(thalamus) or 0.8 ml (cortex) of load buffer (in mM: 140 NaCl, 1.5 KCl, 2
CaCl2, 1 MgSO4, 25 HEPES, and 22 glucose) and placed on ice until
incubation with 86RbCl. Thalamic and cortical synaptosomes were incu-
bated with 4 Ci of 86Rb for 30 min in a final volume of 35 l of load
buffer, after which samples were collected by gentle filtration onto a
6-mm-diameter Gelman-type A/E glass filter and washed once with 0.5
ml of load buffer. Filters containing the synaptosomes loaded with
86Rbwere transferred to a polypropylene platform and superfused for 5
min with effluent buffer (in mM: 135 NaCl, 1.5 KCl, 5 CsCl, 2 CaCl2, 1
MgSO4, 25 HEPES, 22 glucose, 50 nM tetrodotoxin, and 0.1% bovine
serum albumin). A peristaltic pump applied buffer to the top of the
synaptosome containing filter at a rate of 2 ml/min, and a second peri-
staltic pump set at a faster flow rate of 3ml/min removed buffer from the
bottom of the platform. The greater speed of the second pump prevented
pooling of buffer on the filter. Effluent buffer was pumped through a 200
l Cherenkov cell and into a -Ram detector (IN/US Systems, Tampa,
FL). Radioactivity was measured for 3 min with a 3 s detection window
providing 60 data points for each superfusion. Each aliquot was stimu-
lated by 1 of 10 different acetylcholine (ACh) concentrations, with a 5 s
exposure for each concentration.
Neurotransmitter release. After a mouse was killed by cervical disloca-
tion, its brain was removed and placed immediately on ice. The striatal
and hippocampal tissue dissected from each mouse was homogenized in
0.5 ml of ice-cold 0.32 M sucrose buffered with 5 mM HEPES, pH 7.5. A
crude synaptosomal pellet was obtained by centrifugation at 12,000 g
for 20 min at 4°C. The pellets were resuspended in 0.8 ml of “uptake
buffer” (inmM: 128NaCl, 2.4 KCl, 3.2 CaCl2, 1.2 KH2PO4, 1.2MgSO4, 25
HEPES, pH 7.5, 10 glucose). For [ 3H]dopamine uptake, the buffer was
supplemented with 1 mM ascorbic acid and 0.01 mM pargyline. For
[ 3H]GABA uptake, the buffer was supplemented with 1 mM amino-
oxyacetic acid.
For [ 3H]GABA uptake, the crude hippocampal synaptosomes were
incubated for 10 min at 37°C. [ 3H]GABA and unlabeled GABA were
then added to final concentrations of 0.1 and 0.25 M, respectively, and
the suspension was incubated for another 10 min.
For [ 3H]dopamine uptake, striatal synaptosomes were incubated at
37°C in uptake buffer for 10 min before addition of 0.1 M [3H]dopam-
ine and the suspension was incubated for an additional 5 min (Grady et
al., 1997). Because ACh was used as the agonist, the synaptosomes were
treated with diisopropyl fluorophosphate (10 M) during the last 5 min
of the uptake procedure.
All release experiments were conducted at room temperature using
methods described previously (Grady et al., 1997, 2001). In brief, after
3H-neurotransmitter uptakewas complete, aliquots of synaptosomes (80
l) were distributed onto filters and perfused with perfusion buffer [up-
take buffer containing 0.1% bovine serum albumin, 1 M atropine, and
either 10M nomifensine for [ 3H]dopamine release or 0.1MNNC-711
[1-(2-(((diphenylmethylene)amino)oxy)ethyl)-1,2,5,6-tetrahydro-3-
pyridinecarboxylic acid hydrochloride] for [ 3H]GABA release] at 0.7
ml/min for 10 min before fractions were collected. Fractions were col-
lected every 10 s into 96-well plates using a Gilson FC204 fraction collec-
tor (Gilson, Middleton, WI). Optiphase Supermix Scintillation Fluid
(150 l) was added to each well, and radioactivity was determined using
a 1450 MicroBeta Trilux Scintillation Counter (PerkinElmer Life Sci-
ences, Boston, MA). Instrument efficiency was 40%.
Basal 86Rb efflux or neurotransmitter release was calculated by non-
linear least-squares curve fit of the samples before and after the ACh-
stimulated peak to a first-order equation: Ct  C0  e
kt, where Ct is
baseline counts at time t, C0 is baseline counts at t  0, and k is the
first-order constant for basal efflux or release. ACh-stimulated response
was calculated as the difference between the actual sample counts after
ACh stimulation and the estimated basal counts. ACh-stimulated re-
sponse at each concentration was normalized by dividing by the calcu-
lated basal efflux; thus, ACh-stimulated 86Rb efflux or transmitter re-
lease is expressed as the response relative to baseline. EC50 values were
calculated using the following Hill equation: EACh  Emax  [ACh]
nH/
([ACh]nH EC50), where EACh is the response measured after stimula-
tion with ACh concentration [ACh], and nH is the Hill coefficient. Con-
centration–response experiments were fitted with one Hill equation for
transmitter release experiments and the sum of two Hill equations for
86Rb efflux experiments.
125I-Epibatidine binding. Epibatidine binding was used for quantitat-
ing nicotinic receptor levels in various brain regions of WT, Het, and
Hom 4YFP mutant mice as described previously (Whiteaker et al.,
2002). Tissue was collected from the thalamus, cerebral cortex, hip-
pocampus, and striatum, and homogenized in ice-cold 0.1 binding
buffer (inmM: 14.4NaCl, 0.2 KCl, 0.2 CaCl2, 1MgSO4, and 2HEPES, pH
7.5). Homogenates were washed three times by centrifugation (12,000
g; 15 min; 4°C) and resuspension into 0.1 binding buffer and stored at
70°C. For saturation binding experiments, 125I-epibatidine concentra-
tions were varied between 3 and 400 pM. The 200 pM 125I-epibatidine (a
saturating concentration) was used in inhibition binding experiments.
Cytisine inhibition of 125I-epibatidine wasmeasured using drug concen-
trations of 0.1–3000 nM plus a no-drug control. The amount of mem-
brane protein added was chosen to producemaximum ligand binding to
the tissue of1000 Bq/well (5% of total ligand added, minimizing the
effects of ligand depletion) and aminimumof 350 Bq of specific binding.
Membranes were incubated for 2 h at 22°C in 30 l of binding
buffer. Nonspecific binding was determined in the presence of 1 mM
()nicotine tartrate and fell in the range of 20–50 Bq. Incubations were
terminated by filtration onto Gelman GF/F fiber filters using a cell har-
vester, followed by six washes with ice-cold binding buffer. Bound ligand
was measured at 80–85% efficiency using a Packard Cobra gamma
counter (PerkinElmer). Specific binding was calculated for each region
from every animal by subtraction of the relevant nonspecific binding
value. Saturation binding parameters were calculated by fitting data to
the following Hill equation: B  BmaxL
n/(Ln  KD
n), where B is the
binding at the free ligand concentration L, Bmax is themaximumnumber
of binding sites, KD is the equilibrium binding constant, and n is the Hill
coefficient. Inhibition of 125I-epibatidine binding was calculated using a
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two-site fit: B B1/(1 (I/IC50-1)) B2/(1 (I/IC50-2)), where B was
ligand bound at inhibitor concentration I, and B1 and B2 represent
125I-
epibatidine binding to sites sensitive to cytisine inhibition with IC50-1
and IC50-2 (cytisine-sensitive and cytisine-resistant sites, respectively).
125I-mAb 299 labeling. Three mice of each genotype were killed by
cervical dislocation and decapitated, and whole brains were removed.
Brains were rapidly frozen in isopentane (35°C, 10 s) and stored,
wrapped in aluminum foil, at70°C until sliced. Coronal tissue sections
(14 m thick) were obtained using a Leica (Nussloch, Germany) CM
1850 cryostat/microtome, and thaw mounted onto SuperFrost glass
slides (Fisher Scientific, Pittsburgh, PA). Sections were stored, desic-
cated, at70°C until analyzed.
125I-mAb autoradiography was performed as described (Whiteaker et
al., 2006). Sections were allowed to equilibrate to room temperature, and
then rehydrated for 15 min in 100 mM NaCl, 10 mM sodium phosphate
buffer, pH 7.5 (PBS). The hydrated sections were then overlaid with
125I-mAb 299 (0.3 nM) in PBS supplemented with 10 mM NaN3, 10%
(v/v) normal rat serum, and 5% (w/v) protease-free bovine serum albu-
min, and incubated for 48 h (humidified chambers, 4°C). A set of 4 KO
sections was incubated in parallel, for each experiment, to define non-
specific 125I-mAb 299 labeling. Incubated sections were washed in four
changes of PBS (30 min each; 22°C), and then air-dried and desiccated
overnight under vacuum before exposure to Super Resolution phospho-
rimaging screens (PerkinElmer Life Sciences; 2–4 d exposure). Images
were collected using a Packard Cyclone system (PerkinElmer Life Sci-
ences) and quantitated using the associatedOptiQuant software. Regions
were identified by reference to an atlas (Paxinos and Franklin, 2004).
Generally, six separate samples were taken for each region in eachmouse
(exceptionsweremade for very small regions such as the interpeduncular
nucleus, where fewer than six samples were available). For large regions
such as striatum, thalamus, and cortex, samples were taken throughout
the rostral–caudal span of the structure, to ensure that regional hetero-
geneity did not influence the results. Labeling intensity was measured in
terms of digital light units per square millimeter. Specific 125I-mAb 299
labeling in each region was defined by subtracting labeling in the corre-
sponding region of 4 KO brain sections. Studies on 4 knock-out mice
with this procedure show the specificity of our method (Whiteaker et al.,
2006).
Chronic nicotine administration. Chronic nicotine or saline was ad-
ministered to mice using miniosmotic pumps (model 2002; Alzet, Cu-
pertino, CA). On the day of pump implantation, saline or ()-nicotine
hydrogen tartrate (Sigma, St. Louis) was prepared freshly and loaded into
the pump to deliver nicotine at 2 mg  kg1  h1 [which provides max-
imal nAChR upregulation (McCallum et al., 2006) and also provides a
blood concentration of 590 nM (Marks et al., 2004), near the peak con-
centration in the blood of smokers] or 0.4 mg  kg1  h1 with a flow
rate of 0.5 l/h. Surgery was identical with the description of telemetry
probe implantation.
Hot plate. For antinociception experiments, a hot plate was set at 55°C.
A baseline response was determined for each mouse and a cutoff time of
60 s was instituted. The nociceptive time point was indicated by jumping,
paw licking, or rapid thumping of the paw, at which point themouse was
immediately removed from the hot plate. Mice were allowed to recover
for one-half of an hour before the mouse was tested again but with
subcutaneous injectionwith one dose of ()-nicotine at either 0, 1, or 1.5
mg/kg (prepared in saline). Five minutes after the injection, the mouse
was placed again on the hot plate, and the time was noted for reaction to
the nociceptive stimuli of the hot plate. Antinociceptive response was
measured as percentage of maximal possible effect (%MPE) (Marubio et
al., 1999). %MPE [(test control)/(cutoff control)] 100.
Sample preparation for immunohistochemistry and spectral imaging. At
day 10 of chronic infusion of saline or nicotine via miniosmotic pumps,
mice were anesthetized with halothane (2-bromo-2-chloro-1,1,1-
trifluorothane) and subjected to cardiac perfusion first with 20ml of PBS,
pH 7.6, with heparin, secondwith 30ml of 4%paraformaldehyde in PBS,
pH adjusted to 7.6 with Na2HPO4, and finally with 20 ml of 5% sucrose
in PBS, pH 7.6. Thus, animals were perfused and fixed while the minios-
motic pumps were still active. All solutions were on ice. Brains were
dissected and then incubated in 30% sucrose in PBS, pH 7.6, for 3 d at
4°C. The brains were embedded inOCTmedium (Tissue-Tek, Torrance,
CA) and rapidly frozen in 2-methylbutane on dry ice. Coronal and sag-
ittal sections were sliced by cryostat at 30 m and mounted on slides.
Slides with mounted brain sections were stored at20°C. Before imag-
ing, slices were rinsed with PBS, pH 7.6, and mounted with Mowiol and
coverslipped.
Immunohistochemistry. Brain sections on slides were rinsed twice for
10 min with PBS, pH 7.6, and then permeabilized with 0.25% Triton
X-100 in PBS for 5 min. Cultures were rinsed twice for 10 min with PBS
and blocked with 10% donkey serum (Jackson ImmunoResearch, West
Grove, PA) in PBS for 30 min. The primary antibody was diluted in 3%
donkey serum in PBS and incubated for 1 h at 37°C. Brain sections were
thenwashed three times for 5minwith PBS. The secondary antibodywas
diluted in 3% donkey serum in PBS and incubated for 1 h at 37°C. The
incubation and rinsing steps were repeated for second primary antibody
labeling when triple-label immunohistochemistry was performed. Fi-
nally, brain sections were washed three times for 5 min with PBS and
mounted with Mowiol and coverslipped.
The following primary and corresponding secondary antibodies and
their dilutions were used in this study: rabbit anti-MAP2 (microtubule-
associated protein 2) polyclonal antibody at 1:50 (AB5622; Chemicon,
Temecula, CA), CY5-conjugated donkey anti-rabbit (Jackson Immu-
noResearch) at 1:100, mouse anti-GAD67 monoclonal antibody at 1:50
(MAB5406; Chemicon), CY5-conjugated donkey anti-mouse (Jackson
ImmunoResearch) at 1:100, rabbit anti-tyrosine hydroxylase (Pel-Freez,
Rogers, AR) at 1:50, CY5-conjugated donkey anti-rabbit (Jackson Im-
munoResearch) at 1:100, sheep anti-tyrosine hydroxylase polyclonal
(AB1542; Chemicon), andCy3-conjugated donkey anti-sheep IgG (Jack-
son ImmunoResearch).
Spectral confocal imaging. For quantification of 4YFP fluorescence,
images were collected from either of two microscopes equipped with
spectrally resolved multiple detector systems. Each pixel of the X–Y im-
age has complete spectral emission data, comprising the  stack.With an
inverted LSM 510 Meta laser-scanning confocal microscope (Zeiss) us-
ing a Fluar 20, 0.75 numerical aperture (NA) oil immersion objective
(Dickinson et al., 2001; Lansford et al., 2001; Nashmi et al., 2005), images
were collected at wavelengths between 495 and 602 nm with bandwidths
of 10.7 nmduring excitation of YFPwith the 488 nm line of an argon laser
(1–10%; 23–114 W). Pinhole was 1.68 Airy units and a Z resolution of
2.9 m. Images were collected at a 12-bit intensity resolution over
1024 1024 pixels at a pixel dwell time of 6.4 s.
Other spectral images were taken, with excitation at 488 nm, with an
invertedNikonC1si laser-scanning confocalmicroscope (Nikon, Tokyo,
Japan) over 512  512 pixels at 12-bit intensity resolution using a 60
plan apochromat water (1.2 NA) objective. The pinhole was set to a
nominal diameter of 61.3 m. The GAT1-GFP images were excited by a
440 nm modulated diode laser at 20% power.  stacks of images were
acquired at wavelengths between 479 and 634 nm, at 5 nm steps.
In all cases, detector gains and laser attenuators were adjusted to lie
within the linear range of the detector. The output of the appropriate
laser was calibrated at each session with a power meter.
The 4YFP knock-in mice present the advantage that the fluorescent
moiety appears at WT levels rather than overexpressed levels, but this
limits the fluorescence signal. Some brain regions had significant amount
of autofluorescence. We used the capabilities of spectral imaging to de-
convolve specific YFP fluorescence frombackground autofluorescence at
each pixel using a linear unmixing algorithm based on the spectral sig-
natures of YFP and autofluorescence created from reference  stack im-
ages of HEK293T cells expressing soluble YFP and a fixed brain section
fromWT littermates of4YFPmice, respectively (Dickinson et al., 2001;
Lansford et al., 2001; Nashmi et al., 2005).
Image analysis of cell counts,mean intensities, and areameasurements
were done with ImageJ, version 1.37, software (National Institutes of
Health, Bethesda, MD; http://rsb.info.nih.gov/ij/). Details of analyses of
each region are shown in Tables 1 and 2. To calculate themean spectrally
unmixed YFP fluorescence from a particular brain region from aHomor
Het mouse, the corresponding spectrally unmixed residual background
fluorescence from the same brain region of a WTmouse was subtracted.
Calcium imaging in cultured ventral midbrain neurons. Changes in
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[Ca2]i were measured in ventral midbrain neuronal cultures using the
ratiometric fura-2 method as described previously (Nashmi et al., 2003;
Tapper et al., 2004; Fonck et al., 2005). Ventral midbrain tissue [includ-
ing the substantia nigra (SN) and ventral tegmental area (VTA)] ob-
tained from embryonic day 14 embryos was digested with 1 mg/ml pa-
pain, and cells were mechanically separated by gentle pipetting. Cells
were plated onto 35 mm dishes with glass coverslip bottoms in Neuro-
basal culture medium containing 2% B27 supplement, 0.5 mM Glu-
tamax, and 5% horse serum, all obtained from Invitrogen. Cell cultures
were kept in a temperature-, humidity-, and CO2/O2-controlled incuba-
tor. Measurements were made at 28–35 d in culture. For experiments
with chronic nicotine, 10 nM was applied for 3 d and removed 1 h
before the imaging experiments. During this 1 h period, cells were loaded
with 1.25 M fura-2 AM (Invitrogen) in a 0.01% pluronic acid solution
for 30 min at room temperature (22  2°C) and in the dark. During
experiments, cultures were continually perfused with an extracellular
solution (in mM: 150 NaCl, 10 HEPES, 10 glucose, 4 KCl, 2 CaCl2, and 2
MgCl2). Various channel blockers to suppress nonspecific responses
were included in the extracellular solution as follows (in M): 0.5 TTX
(voltage-gated Na channels), 0.5 atropine (muscarinic receptors), 10
CNQX (AMPA and kainate receptors), 20 bicuculline (GABAA recep-
tors), 50 AP-5 (NMDA receptors), and 0.01 methyllycaconitine (MLA)
(7 receptors). Ascorbic acid at 1 mM was also added to the extracellular
solution to protect neurons from photodamage. Imaging was performed
with an inverted fluorescencemicroscope (IX71;Olympus,Melville, NY)
using a 40 oil-immersed objective (UApo/340; 1.35 NA). To generate
ratiometric estimates of [Ca2]i, pairs of images were obtained with
alternate excitationwavelengths of 340/380 nm and emissionwavelength
of 510 nm. A U-tube connected to a pipette, placed0.5 mm away from
the targeted cell population, was used to deliver nicotine. Nicotinic re-
ceptors desensitize at agonist concentrations too low to cause appreciable
activation; therefore, between applications, negative pressure was main-
tained on the U-tube to prevent nicotine from leaking out of the pipette.
Nicotine was applied onto cultured cells when solution flow in the
U-tube was momentarily (2 s) reversed by stopping outflow with a
computer-controlled valve. Images were captured with a 16 bit CCD
camera (Cascade 650; Photometrics, Tucson, AZ) and analyzed with
Slidebook 4.1 imaging software (Intelligent Imaging Innovations, Den-
ver, CO).
Whole-cell patch-clamp electrophysiology of cultured ventral midbrain-
neurons. Cultures were prepared and maintained as described in the
fura-2 experiments. Whole-cell recordings were performed with glass
electrodes (2–5M	) filled with an internal solution [inmM: 88 KH2PO4,
4.5 MgCl2, 0.9 EGTA, 9 HEPES, 0.4 CaCl2, 14 creatine phosphate, 4
Mg-ATP, and 0.3 GTP (Tris salt), pH 7.4 with KOH] (Nashmi et al.,
2003; Fonck et al., 2005). Channel blockers to suppress nonspecific re-
sponses were included in the extracellular solution (in M: 0.5 TTX, 0.5
atropine, 10 CNQX, 20 bicuculline, 50 AP-5, and 0.01MLA). Recordings
were made using an Axopatch 1D (Molecular Devices, Union City, CA)
amplifier, low-pass filtered at 2–5 kHz, and digitized on-line at 20 kHz
(pClamp 8; Molecular Devices). The membrane potential was held at
70 mV. The 3 M ACh test pulses lasting 250 ms were delivered with a
two-barrel glass theta tube pulled from borosilicate tubing and con-
nected to a piezoelectric translator (LSS-3100; Burleigh Instruments,
Fishers, NY).
Patch-clamp electrophysiology on midbrain slices. The patch-clamp ex-
periments were conducted blind to the contents of the osmotic
minipumps (nicotine vs saline) until the conclusion of recording from
each group of implanted mice. P30–P38 mice were deeply anesthetized
with sodium pentobarbital (40mg/kg). Then, cardiac perfusion was per-
formed using ice-cold glycerol-based artificial CSF (gACSF), containing
252 mM glycerol, 1.6 mM KCl, 1.2 mM NaH2PO4, 1.2 mM MgCl2, 2.4 mM
CaCl2, 18 mM NaHCO3, and 11 mM glucose, and oxygenated with
95%O2/5%CO2. After decapitation, the brain was removed and kept in
gACSF (0–4°C), andwas cut into 250–300m thick slices in the coronal
plane (DTK-1000; Microslicer; Ted Pella, Redding, CA). The slices were
allowed to recover for at least 1 h in regular artificial CSF (aCSF), con-
taining 126mMNaCl, 1.6 mMKCl, 1.2 mMNaH2PO4, 1.2 mMMgCl2, 2.4
mM CaCl2, 18 mM NaHCO3, and 11 mM glucose, and oxygenated with
95% O2/5% CO2.
A single slice was transferred to the 0.8 ml recording chamber.
Throughout the experiments, the bath was continually perfused with
aCSF (1.5–2.0ml/min). Cells were visualizedwith an uprightmicroscope
(BX 50WI; Olympus) and near-infrared illumination. The patch elec-
Table 1. 4YFP intensities in ventral midbrain neurons
Cell-based measurements (no. of cells)
Saline (6 mice) Nicotine (6 mice)
Saline Nicotine Nicotine, % of saline p value Total 4 Total 4
VTA (TH) 826 22 902 23 109 3 NS 640 610 655 648
VTA (GAD) 268 25 363 18 136 7 0.002 73 67 100 99
SNC (TH) 1052 23 1117 25 106 2 NS 612 610 581 579
SNR (GAD) 503 17 735 18 146 4 0.001 256 254 237 237
Measurements of4YFP fluorescence in various brain regions and changeswith chronic nicotine (2mg  kg1  h1 for 10d). Procedureswere applied to eachof the sixmice in eachgroup.Unless otherwise stated, analyseswereperformed
on one brain section per mouse. In VTA, all TH or GAD somata were measured. In SNC, TH or GAD cell bodies were measured in one of two lobes. NS, Not significant; no., number.
Table 2. 4YFP intensities in various brain regions
Area-based measurements (m2)
Saline Nicotine Nicotine, % of saline p value Saline (6 mice) Nicotine (6 mice)
Superior colliculus 195 20 262 21 134 12 0.027 11 105 12 105
Medial habenula 669 55 749 24 112 4 NS 1.7 105 1.6 105
Fasciculus retroflexus 599 86 673 41 112 7 NS 2.8 105 1.8 105
Interpeduncular nucleus 1216 71 984 38 81 3 0.01 3.0 105 2.3 105
Perforant path 287 8 555 7 194 2 0.001 5.2 105 4.1 105
Nucleus accumbens 318 25 357 18 112 6 NS 21 105 21 105
Caudate putamen 353 11 417 15 118 4 0.002 31 105 29 105
Cerebral cortex 273 18 236 16 86 6 NS 13 105 11 105
Anterior cingulate cortex 299 21 407 23 136 8 0.001 7.2 105 7.5 105
Thalamic DLG nucleus 840 71 928 38 111 4 NS 10 105 11 105
Measurements of4YFP fluorescence in various brain regions and changeswith chronic nicotine (2mg  kg1  h1 for 10d). Procedureswere applied to eachof the sixmice in eachgroup.Unless otherwise stated, analyseswereperformed
on one brain section permouse. Area-basedmeasurements were conducted as follows: superior colliculus, four regions, 150mmost dorsal aspect; medial habenula, lower two-thirds of each of two lobes; fasciculus retroflexus, two cross
sections; interpeduncular nucleus, two sections; perforant path, four regions in the lower limbs of themedial perforant path; nucleus accumbens, two regions; caudate putamen, four regions in the dorsal aspect; cerebral cortex, two regions
in layers 2–5 in the barrel cortex somatosensory area; anterior cingulate cortex, two regions 75m frommidline in two brain sections per mouse; and thalamic dorsolateral geniculate (DLG) nucleus, one region in each of the two nuclei.
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trodes had a resistance of 5–8 M	 when filled with pipette solution: 135
mM potassium gluconate, 5 mM EGTA, 0.5 mM CaCl2, 2 mM MgCl2, 10
mM HEPES, 2 mM Mg-ATP, and 0.1 mM GTP, pH adjusted to 7.2 with
Tris base, osmolarity adjusted to 280–300 mOsm with sucrose. Whole-
cell current-clamp was performed at 32°C with a MultiClamp 700B am-
plifier (Molecular Devices), a Digidata 1200A A/D converter, and
pCLAMP9.2 software (MolecularDevices).Datawere sampled at 10 kHz
and filtered at 2 kHz. The junction potential between the patch pipette
and the bath solution was nulled just before gigaseal formation.
We verified the putative GABAergic neurons in the substantia nigra
pars reticulata (SNR) and putative dopaminergic neurons in the substan-
tia nigra pars compacta (SNC) (supplemental Fig. S6, available at www.
jneurosci.org as supplemental material), according to generally accepted
criteria (Lacey et al., 1989; Wooltorton et al., 2003): (1) narrow spikes in
putative SNR GABAergic neurons, broad spikes in putative SNC dopami-
nergic neurons (supplemental Fig. S6A, available at www.jneurosci.org
as supplemental material); (2) rapid firing in putative SNR GABAergic
neurons, but slow firing in putative SNCdopaminergic neurons (supple-
mental Fig. S6B, available at www.jneurosci.org as supplemental mate-
rial); (3) putative SNC dopaminergic neurons, but not putative SNR
GABAergic neurons, express hyperpolarization induced cationic current
(Ih) (supplemental Fig. S6C, available at www.jneurosci.org as supple-
mental material). In addition, in select experiments putative SNR
GABAergic neurons and putative SNC dopaminergic neurons were
respectively inhibited or disinhibited by DAMGO (Tyr-D-Ala-Gly-
MePhe-Gly-ol) (1 M), a -opioid receptor agonist; and putative SNC
dopaminergic neurons, but not putative SNR GABAergic neurons (sup-
plemental Fig. S6D, available at www.jneurosci.org as supplemental ma-
terial), are inhibited by quinpirole (0.2 M), a D2/D3 receptor agonist
(Lacey et al., 1989; Wooltorton et al., 2003) (supplemental Fig. S6E,
available at www.jneurosci.org as supplemental material). Given the
good agreement between these criteria and the localization of these neu-
rons (SNC vs SNR), we drop the term “putative,” and subsequently,
neurons were routinely characterized by location and spike duration.
To examine the function of nAChRs in SNRGABAergic neurons, 1M
nicotine was focally puffed (5 s), using a picospritzer driven pipette at-
tached to a piezoelectric translator (Tapper et al., 2004). The pipette was
moved within 20mof the recorded cell over a period of 250ms starting
300msbefore drug application.Nicotinewas thenpuffed at 10–20 psi for
5 s. Fifty milliseconds after the puff, the glass pipette was retracted over a
period of 250 ms. For dopaminergic recordings of nicotinic responses,
because we could not determine the connectivity between GABAergic to
dopaminergic neurons, it was inappropriate to use a focal drug applica-
tor such as a picospritzer. Therefore, on recording of dopaminergic neu-
rons, nicotine (1 M) was bath applied for 5 min. This enabled nicotinic
receptors to be activated on all GABAergic and dopaminergic neurons
within the slice.
Long-termpotentiation electrophysiology.AdultHom4YFPmice (2–3
months), treated with saline or nicotine for 10 d, were killed by cervical
dislocation, and the brain was rapidly removed (50 s) and placed in
aerated (95% O2/5% CO2) ice-cold aCSF of the following composition
(in mM): 124 NaCl, 3 KCl, 2.4 CaCl2, 1.3 MgSO4, 1.25 NaH2PO4, 26
NaHCO3, and 10 glucose. After 4 min, the brain was hemisected and
glued with cyanoacrylate glue dorsal side down and rostral side closest to
the blade. Horizontal sections (400 m) of the hippocampus were made
with a vibratome (DSK Microslicer; model DTK-1000; Ted Pella) and
allowed to recover for 
1 h at room temperature. The slice was trans-
ferred to a submersion chamber (catalog #65-0073 and 65-0074;Harvard
Apparatus, SouthNatick,MA)maintained at 32°C. TheGABAA receptor
blocker, bicuculline (10 M), was added to the aerated aCSF during
recording to relieve the strongGABAergic inhibition of the dentate gyrus
(Colino and Malenka, 1993; Yun et al., 2005). Thus, brain tissue was
removed from contact with the miniosmotic pump for periods of 2–8 h.
Stimulation of the medial perforant path was provided by bipolar
stimulating electrodes fabricated from Formvar-coated Nichrome wires
(50 m bare diameter; catalog #762000; A-M Systems, Carlsborg, WA).
Stimulating and recording electrodes were positioned in the suprapyra-
midal limb of the dentate gyrus in the middle one-third of the molecular
layer to stimulate and record dendritic field EPSPs (fEPSPs). Recording
electrodes (2–6 M	) were pulled from borosilicate pipettes (catalog
#1B150F-4; WPI, Sarasota, FL) and filled with aCSF. Stimulating elec-
trodes were placed200m from recording electrodes. Responses were
recorded on an Axoclamp-2A amplifier (Molecular Devices), amplified
1000, low-pass filtered at 3 kHz, and digitized at 10 kHz. An input–
output relation for fEPSP slope was measured by varying the stimulus
intensity (5–100 A; 100 s duration). The stimulus intensity that elic-
ited 40%of themaximal slopewas applied as test pulses and tetanic trains
during long-term potentiation (LTP) experiments. Paired-pulse stimuli
with a 50 ms interval were applied to check for fEPSP paired-pulse inhi-
bition, indicating that stimulating and recording electrodes were located
in the medial perforant path (Colino and Malenka, 1993; Yun et al.,
2005). A steady baseline of fEPSP slopes was recorded for 20 min with a
stimulation rate of 1 in 30 s. LTP was induced by three trains of 100 Hz,
each 1 s in duration, at 4.5min intervals. Responses were recorded there-
after for a period of 60 min. The magnitude of LTP was measured by
averaging the percent increase of the fEPSP slope comparedwith baseline
at 40–60 min after tetanic stimuli.
Statistical analysis.All values are reported as mean SEM. Significant
differences (at p 0.05) were determined between two groups using a t
test for continuous data meeting parametric assumptions of normality
and equal variance. Otherwise, the Mann–Whitney rank sum test was
used for nonparametric data.
Results
We created a knock-in mouse strain whose 4 subunits are re-
placed by subunits containing yellow fluorescent protein (4YFP
subunits), which was inserted in-frame within the M3–M4 cyto-
plasmic loop of 4 (Nashmi et al., 2003). Previous data in trans-
fected systems show that receptor function remains unaffected by
this insertion (Nashmi et al., 2003); the knock-in strategy now
places the 4YFP subunit under the control of the same promot-
ers, enhancers, and trafficking mechanisms as WT 4 subunits,
and provides cellular and subcellular resolution in the normal
physiological milieu of the intact animal.
Characterizing the4YFPmice: normal nicotinic
receptor function
We proceeded to quantify the relative amount of 4 nAChR sub-
units in various brain regions. Figure 1 displays a series of mon-
tages of confocal images of a coronal brain section showing the
overall distribution of 4 at the level of the hippocampus/thala-
mus (Fig. 1E; bregma,1.58).We imaged stacks over a spectral
range (supplemental Fig. S1, available at www.jneurosci.org as
supplemental material), enabling us to isolate specific YFP fluo-
rescence from autofluorescent background using reference spectra
of YFP (cells transfected with soluble YFP) and autofluorescence (a
fixed brain slice of a wild-type mouse). Summarizing data from 16
different brain regions inWT,Het, andHommice, the highest level
of 4 expression was in the medial habenula, followed by the thala-
mus, SNC, and the interpeduncular nucleus. Moderate levels of 4
expression were found in the superior colliculus, cerebral cortex,
retrosplenial granular cortex, and subiculum. This pattern agrees
well with previous data (Swanson et al., 1987; Marks et al., 1992;
Whiteaker et al., 2006). When 4YFP fluorescence is totaled for
these 16 brain regions, the Het mouse brain fluorescence is approx-
imately one-half (45%) that of Hom, consistent with straightfor-
ward gene dosage.
Detailed analyses of expression in ventral midbrain and in
hippocampus are presented below (see Figs. 3–7); here, we
present a survey of other areas. Most of the thalamus expressed
strong 4YFP fluorescence (Fig. 1E). 4YFP was localized
strongly in neuronal cell bodies, dendrites, and axons (supple-
mental Fig. S5, available at www.jneurosci.org as supplemental
material). In addition to prominent fluorescence in the presum-
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ably glutamatergicneuronsofmost thalamic
nuclei, we noted 4YFP in the cell bodies of
GABAergic neurons of the reticular thalamus
(supplemental Fig. S5, available at www.
jneurosci.org as supplemental material).
In most neocortical areas, neuronal cell
bodies contained low 4YFP fluorescence
levels (data not shown). However, signifi-
cant 4YFP fluorescence was detected in
diffuse axonal fibers innervating the cortex
(data not shown). In the anterior cingulate
cortex, two parallel medial bands of
4YFP fluorescence appeared outside the
cell body layer (data not shown). 4YFP
was also detectable in axonal fibers in the
internal capsule (supplemental Fig. S5G,
available at www.jneurosci.org as supple-
mental material), which comprise tha-
lamic and cortical fibers.
We used a battery of functional, bind-
ing, immunolabeling, and behavioral as-
says to examine whether inserting YFP in
the 4 nAChR subunit altered the func-
tion or expression in vivo. First, whole-cell
patch-clamp recordings were performed
on cultured ventral midbrain neurons
from both Hom and WT mice. Nicotinic
currents were elicited by application of a
low (3 M) and a nearly saturating dose
(300 M) of ACh, using a theta tube at-
tached to a piezoelectric translator. Nico-
tinic currentswere positively identified be-
cause the currents were reversibly blocked
by the competitive antagonist DHE
(dihydro--erythroidine) (1 M) (supple-
mental Fig. S2A, available at www.jneurosci.
org as supplemental material). Further-
more, other receptors and channels were
blocked using atropine, TTX, AP-5,
CNQX, bicuculline, and MLA. The aver-
age nicotinic peak current densities were
about the same inWT as inHomneuronal
cultures (supplemental Fig. S2A, available
at www.jneurosci.org as supplemental
material).
Fura-2 imaging and dose–response re-
lationships were performed on cultured
ventral midbrain neurons. Various doses
of ACh demonstrated nearly identical
dose–response relationships of nicotinic
responses between WT and Hom neuronal cultures in the pres-
ence of receptor and channel blockers that isolated nicotinic re-
sponses (supplemental Fig. S2B, available at www.jneurosci.org
as supplemental material).
The effects of 4YFP expression on measures of nAChR levels
and function in preparations from adult mouse brain are illustrated
in Figure 2. Maximal response and EC50 values for ACh-stimulated
86Rb efflux measured in thalamus and cortex (data not shown),
dopamine release in striatum, and GABA release in hippocampus
were similar in4YFPHom andHet andWTmice (Fig. 2A). Total
high-affinity 125I-epibatidinebinding aswell as the cytisine-sensitive
and cytisine-resistant components of these sites in striatum, cortex,
thalamus, and hippocampus of Hom and Het 4YFP mice did not
differ from that ofWTmice (Fig. 2B), indicating that the expression
of nicotinic binding sites was unaffected by YFP insertion. Consis-
tent with these observations, binding of 125I-mAb299, which specif-
ically labels the4 subunit (Whiteaker et al., 2006)wasunaffectedby
YFP insertion (Fig. 2C).
Previous work showed that 4* nAChRs mediate nicotine-
induced antinociception on the hot plate (Marubio et al., 1999;
Damaj et al., 2007). WT, 4YFP, and 4 KO (Ross et al., 2000)
mice showed similar baseline reaction times to sensing pain on
the hot plate. Similar to the previous studies (Marubio et al.,
1999; Damaj et al., 2007), we found that 4 KOmice (Ross et al.,
2000) are relatively resistant to nicotine-induced antinocicep-
tion, whereas 4YFP Hom, Het, and WT mice showed similar
Figure1. Construction of the4YFPmouse andwhole-brain fluorescence.A, Genomicmapof thewild-typemouse4nAChR
allele located on chromosome 2 (top). Targeting vector was constructed with the4 gene including exons 5 and 6 and the YFP
mutation inserted in the pKO V907 vector (second line; note an inserted HA-epitope tag immediately upstream of YFP is not
shown). The neomycin-resistance gene (neo) flanked by loxP sites and the diphtheria toxin A (DT ) gene were also inserted as
positive and negative selection markers. Map of the recombined4 gene (third line). The neo cassette was deleted by electro-
porating the neo-intact ES cells with a cytomegalovirus-Cre plasmid to generate neo-deleted ES cell lines (fourth line). Restriction
sites: A, AvrII; B, BstEII; Sc, SacI; Sp, SpeI. B, Chromatogram showing the start of the YFP sequence and the upstream HA-epitope
tag in the4 nAChR gene. C, PCR genotyping of WT, Het, and Hom4YFP mice. D, RT-PCR showing4 mRNA expression from
combined thalamic–ventralmidbrain tissue fromHet andWTmice. The highermolecularweight band in theHet ismessage from
the4YFPallele.Negative controls, lacking reverse transcriptase in theRT-PCR,weredevoidofbands.E,Montageof tiled confocal
images of a coronal brain section at thehippocampal level fromaHom4YFPmouse showingoverall brain distribution of4YFP.
F, Quantification of4YFP fluorescence using spectral confocal imaging taken from various brain regions from brain sections of
WT,Het, andHom4YFPmice. Thehorizontal bar plots showmean4YFP intensity (SEM) forHet andHommice for eachbrain
region.Residual autofluorescence intensity fromWTmiceare shown inbrackets and subtracted fromthe raw intensity values from
Het and Hom. CauPut, Caudate–putamen; NuAcSh, nucleus accumbens shell; NuAcCo, nucleus accumbens core; VerDiaB, vertical
diagonal band;Med Sep,medial septum; Cerebel, cerebellar cortex; S1 CerCort, primary somatosensory cortex of barrel and trunk;
RGS Cer Cor, retrosplenial granular cerebral cortex; Sup Coll, superior colliculus; Red Nuc, red nucleus; Hip Neur, hippocampal
interneurons; Hip PerfP, hippocampal medial perforant path; Thal, dorsolateral geniculate nucleus of thalamus; MHb, medial
habenula; IPN, interpeduncular nucleus. The “Average” bars show the4YFP fluorescence averaged for the various regions for
both Het and Hommice.
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pharmacological sensitivity to nicotine-induced antinociception
(supplemental Fig. S3, available at www.jneurosci.org as supple-
mental material). In data not shown, we also found that nicotine
produces hypothermia equally in 4YFP
Hom, Het, and WT mice.
Thus, using electrophysiology, fura-2
imaging, radiolabeled agonist binding, ra-
diolabeled Rb efflux, neurotransmitter
release, immunolabeling, and behavioral
measurements, we found that 4YFP
nAChRs in knock-in mice functioned and
expressed like wild-type receptors. These
data form the basis for examining changes
produced by chronic exposure to nicotine.
Nicotine-induced4YFP upregulation
in midbrain GABAergic neurons
Dopaminergic reward systems include
highly nicotine-sensitive neurons in the
VTA and SNC (Stolerman and Shoaib,
1991; Mirenowicz and Schultz, 1996;
Schultz et al., 1998; Hyman et al., 2006),
and an accurate map of high-sensitivity
nicotinic receptor expression in this re-
gion would further our understanding of
the precise actions of nicotine. Therefore
we labeled specific neuronal subpopula-
tions within this region using cell-type
specific markers, specifically dopaminer-
gic neurons (tyrosine hydroxylase) versus
GABAergic neurons (GAD67).
Figure 3 shows images of4 expression
in the ventral midbrain with tyrosine hy-
droxylase double label for dopaminergic
neurons; triple labeling with GAD67 was
also performed. The tabulated data (Ta-
bles 1, 2) show that nearly all neurons in
the SNC are dopaminergic and 
99%
contain 4, as expected. In the VTA, 90%
of neurons are dopaminergic, whereas
10% are GABAergic, as expected (Johnson
and North, 1992). Of the GABAergic VTA
neurons, 92% had detectable levels of
4YFP fluorescence (Fig. 4), extending
previous data (Yin and French, 2000;
Klink et al., 2001; Mansvelder et al., 2002).
In the SNR, 99% of the GABAergic neu-
rons contained 4, extending previous
data (Klink et al., 2001) (Fig. 4) (described
inmore detail below).4YFP fluorescence
in dopaminergic neurons of the VTA and
SNC had approximately twice the inten-
sity of that found inGABAergic neurons in
the SNR (Fig. 3B–D); but these data show,
for the first time, that nearly all VTA and
SNR GABAergic neurons express 4* re-
ceptors.4YFPwas also found in dopami-
nergic and nondopaminergic fibers of the
dorsal striatum and was also detectable in
dopaminergic fibers innervating the nu-
cleus accumbens (supplemental Fig. S4,
available at www.jneurosci.org as supple-
mental material).
We performed experiments to quantitate the effect of chronic
nicotine on 4* receptor levels in 4YFP mice. Nicotine at 2
mg  kg1  h1 or saline was infused for 10 d via miniosmotic
Figure2. Ion flux, transmitter release, agonist binding, and immunohistochemistry data.A, Left, Dose–response relationships
for ACh evoked 86Rb effluxmeasurements from synaptosomesmade from thalamic tissue fromWT,Het, andHom4YFPmice.
Data were fitted to two (H, L) components. ForWT, EC50H 2.6 0.7M, EC50L 79 35M; Het, EC50H 3.2 0.4M,
EC50L 54 9M; Hom, EC50H 2.8 2.7M, EC50L 75 110M.Middle, Right: Dose–response relationships of GABA
(middle) and dopamine (right) release from the hippocampal and striatal synaptosomes, respectively, from WT, Het, and Hom
4YFPmice.Datawere fitted toa single component includingaHill coefficient (n). GABA release:WT, EC503.70.49M,n
0.560.25;Het, EC503.51.34M,n0.940.29;Hom, EC505.11.8M,n1.00.32. Dopamine release:WT,
EC50 0.57 0.09M, n 0.93 0.14; Het, EC50 0.56 0.05M, n 0.97 0.09; Hom, EC50 0.61 0.18M, n
1.00.29.B, Concentrationdependenceof 125I-epibatidinebinding in themembrane fractionof thalamus, cortex, striatum,and
hippocampus from WT, Het, and Hom 4YFP mice. 125I-Epibatidine binding was performed in the presence and absence of
cytisine to determine the cytisine-sensitive and cytisine-resistant sites. The cytisine-sensitive binding sites are likely 42
nAChRs. C, Quantitative autoradiography of 125I-mAb 299 labeling in WT, Het, and Hom 4YFP mice. Representative coronal
sections are shown at the hippocampal level. Nonspecific labelingwas defined in parallel sets of sections from4/mice, and
was subtracted from total signal to define regional specific labeling. The histogram showsmean regional specific labeling densi-
ties (SD) for each genotype. Abbreviations are as in Figure 1H.
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pumps to 4YFP Hom mice; and 4YFP
fluorescence was measured in various
brain regions to examine potential
changes in 4* nAChR levels (Tables 1, 2).
Surprisingly, 4YFP fluorescence did not
change significantly from control to
nicotine-treated mice in dopaminergic
neurons of both SNC (106  2%) and
VTA (109  3%). However, GABAergic
neurons of both SNR (146  4%) and
VTA (136 7%) showed significant ( p
0.001 and p  0.002, respectively) in-
creases in4YFP fluorescence (Tables 1, 2;
Fig. 4). With a lower dose of nicotine (0.4
mg  kg1  h1), there was also a larger
increase in 4YFP fluorescence in
GABAergic neurons of SNR (117  2%)
compared with dopaminergic neurons of
VTA (102  4%) and SNC (110  3%)
(data not shown). These data in midbrain
indicate differential receptor level changes
in response to chronic nicotine, specific to
neuronal subpopulations.
We acknowledge that the brain slice
patch-clamp studies (described below)
were performed on mice 30–38 d of age,
and the experiments of Tables 1 and 2 on
mice 67–69 d of age. To diminish the pos-
sibility that these two age groups respond
differently to chronic nicotine, we per-
formed pilot experiments on fluorescent
imaging in4YFPmice 42–52 d of age.We
observed selective upregulation of 4YFP
fluorescence in GABAergic but not dopa-
minergic neurons, as in Tables 1 and 2.
Chronic nicotine increases firing
frequency in GABAergic, but not
dopaminergic neurons, in response to
acute nicotine
Because it is crucial to investigate the func-
tional state of upregulated receptors, we
sought to determine how neuronal signal-
ing changed in these chronically treated
circuits.We performed direct electrophys-
iological experiments on GABAergic com-
pared with dopaminergic neurons in mid-
brain slices. The electrophysiological
criteria for distinguishing dopaminergic
versus GABAergic cells in rodent VTA are
now uncertain (Ford et al., 2006; Margolis
et al., 2006); we therefore studied neurons
in the substantia nigra, where the dopami-
nergic and GABAergic cells occupy dis-
tinct subnuclei (SNC and SNR, respec-
tively). We also found that SN neurons
maintained their health much better than
VTAneurons in slices from young animals
that had been implanted for 10 d with os-
motic minipumps. The recorded neurons
in SNR and SNC did display the respective
electrophysiological and pharmacological
characteristics thought to distinguish
Figure3. Stainingandquantificationof dopaminergic andGABAergic4YFP-containingneurons in the SNandVTA.A, Double
labeling showing4YFP (green) in most TH dopaminergic (red) neurons in the VTA and SNC. Intense4YFP labeling is found
in the interpeduncular nucleus (IPN) and light4YFP fluorescence is found in the SNR. B, Triple labeling at higher magnification
showing strong4YFP (green) fluorescence in dopaminergic neurons (TH; blue) of the SNC andmoderate4YFP fluorescence in
GABAergic neurons (GAD67; red) of the SNR. C, D, Quantification of 4YFP intensities per TH dopaminergic and GAD67
GABAergic neuron in either the VTA, SNC, or SNR are shown with box plots (C) and histogram distributions (D).
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GABAergic and dopaminergic neuron types (i.e., action potential
duration, firing frequency, presence of Ih, effects of a -opioid
agonist, and effects of a dopamineD2 agonist) (supplemental Fig.
S6, available at www.jneurosci.org as supplemental material).
Whole-cell patch-clamp recordings were conducted on ven-
tral midbrain slices prepared from mice (ages, 30–38 d) chroni-
cally treated with nicotine for 10 d. Although these mice were
younger than those studied in the fluorescence experiments,
nAChR receptor levels in ratmidbrain dopaminergic areas do not
change markedly after day 30 (Azam et al., 2007). In the absence
of nicotine, GABAergic neurons from chronically nicotine-
treated mice displayed significantly higher baseline firing rates
than neurons from chronically saline-treated mice (17.9  1.4
Hz, n 12, vs 12.4 1.7 Hz, n 18; p 0.03) (Fig. 5). This is
consistent with the presence of endogenous acetylcholine during
the recording, released from the terminals of severed axons of
hindbrain cholinergic neurons in the ventral midbrain slice. The
inverse was the case for dopaminergic neurons in the absence of
acute nicotine. Dopaminergic neurons from chronic nicotine-
treated mice had significantly lower basal action potential firing
rates than chronic saline-treatedmice (1.93 0.17Hz, n 17, vs
2.64  0.25 Hz, n  21; p  0.016) (Fig. 6A,B). These data
indicate that the functional effects of chronic nicotine corre-
spond to the numerical upregulation observed.
To further test the efficacy of these upregulated receptors, we
compared direct nicotine effects in GABAergic neurons from
chronically nicotine- or saline-treatedmice.When 1M nicotine
was puffed for 5 s using a picospritzer, GABAergic neurons from
chronically nicotine-treatedmice also displayed greater increases
in peak firing rates than neurons from saline-treated mice
(16.1  3.2 Hz, n  6, vs 8.2  2.0 Hz, n  6; p  0.03) (Fig.
5A,C). These responses were absent in slices perfused with 5 M
mecamylamine (data not shown). Dopaminergic neurons within
the SNC are direct downstream synaptic targets of GABAergic
neurons within the SNR. Therefore, we sought to address
whether alterations in GABAergic firing frequency caused by the
presence of upregulated receptors would affect the electrophysi-
ological properties of SNC dopaminergic neurons. To perform
this, we bath applied 1 M nicotine to slices to drive nicotine
activation in both GABAergic neurons in the SNR and their
Figure 4. Histograms and cumulative plots showing changes in4YFP fluorescence in do-
paminergic and GABAergic neurons of the SN and VTA with chronic nicotine. Histogram and
cumulative plots of the mean 4YFP fluorescence per TH (dopaminergic) or GAD67
(GABAergic) neuron from4YFPHommice treatedeitherwith chronic salineor chronicnicotine
(2 mg  kg1  h1) for 10 d.4YFP fluorescence was imaged from VTA, SNC, and SNR from
brain sections triple labeledwith TH,GAD67, and4YFP.Dopaminergic neurons in SNCandVTA
show very little change in 4YFP. However, GABAergic neurons in VTA and SNR show a shift
(increase) in4YFP intensity with chronic nicotine.
Figure 5. Patch recordings frommidbrain GABAergic neurons in slices frommice exposed to
chronic nicotine or saline. A, Chronic nicotine treatment enhanced baseline firing rate in SNR
GABAergic neurons. Typical traces (0.5 s) (a, baseline; b, peak; c, wash) and time course of firing
also show that puff application (5 s) of nicotine (1 M) increased firing rate in neurons from
chronic saline (top traces and empty circles)- and nicotine (bottom traces and filled circles)-
treated mice. B, C, Summary of nicotine-induced increment of firing rate in SNR GABAergic
neurons. Data in time course and summary are shown as mean SEM.
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postsynaptic targets, dopaminergic neurons in SNC. In these
studies, chronic nicotine plus acute nicotine produced a smaller
increase in dopaminergic firing than chronic saline plus acute
nicotine (0.55  0.27 Hz, n  8, vs 1.25  0.23 Hz, n  8; p 
0.04) (Fig. 6A,C). Figure 8 provides a schematic explanation for
these findings; but in brief, the accelerated firing in the GABAer-
gic neurons and resulting increased inhibition apparently damp-
ened baseline firing in dopaminergic neurons and also blunted
the direct excitatory effect of nicotine responses on dopaminergic
cells themselves. Therefore, we conclude that chronic nicotine
increases both the baseline firing rate and the excitatory effect of
1 M nicotine in GABAergic neurons, while decreasing baseline
firing rate and attenuating the excitatory effect of 1Mnicotine in
dopaminergic neurons. These data suggest that alterations in do-
paminergic signaling caused by chronic nicotine could be ac-
counted for by receptor upregulation within GABAergic neurons
and that increases in inhibition could provide an explanation for
tolerance to the chronic effects of nicotine.
Because dopaminergic neurons in mice chronically exposed
to nicotine did not respond vigorously to acutely applied nico-
tine, one asks whether there is amechanism imposing a ceiling on
nicotine response in dopaminergic neurons. This point should be
viewed in light of previous experiments in our laboratory on the
dopaminergic neurons of 4Leu9Ala knock-in mice (Tapper et
al., 2004). The Leu9Ala mice were specifically designed to ex-
press hyperactive 4* receptors in place of WT receptors. In do-
paminergic neurons from drug-naive Leu9Ala mice, acutely ap-
plied 1 M nicotine produced significantly greater nicotine
responses, and nicotine-induced firing, than inWTmice (Tapper
et al., 2004). (Electrophysiological experiments have not been
performed on chronic nicotine-treated Leu9Alamice.) The data
for the Leu9Ala mice allow one to state that significantly in-
creased 4* sensitivity in dopaminergic neurons can, at least in
some cases, result in increased nicotine-induced firing. The ap-
parently unchanged sensitivity in dopaminergic neurons in the
present experiments is therefore not likely to result from satu-
rated receptors, unusual spike-generating properties, or unusual
cable properties of dopaminergic cells.
4YFP upregulation in the perforant path of
the hippocampus
Fluorescence measurements
4YFP expression was strong in several glutamatergic fiber tracts
innervating the hippocampus: the medial perforant path, the
temperoammonic path, and the alveus (Fig. 7A). Chronic nico-
tine produced the largest 4YFP fluorescence increase in the me-
dial perforant path, which contains axons of layer 2 medial ento-
rhinal cortical neurons and is located in the middle one-third of
the molecular layer surrounding the dentate granule layer.
After 2 mg  kg1  h1 nicotine administration for 10 d, the
4YFP fluorescence in the medial perforant path was 94  2%
greater than control ( p  0.001) (Tables 1, 2). At 0.4
mg  kg1  h1 nicotine infusion, the increase in4YFP fluores-
cence was approximately one-half (44 5%; p 0.001) of that at
the higher dose (data not shown), in agreement with previous
dose–response data for upregulation of likely 42 receptors in
mouse brain (Pauly et al., 1991; Marks et al., 2004).
Functional upregulation measured with LTP
LTP, a form of synaptic plasticity related to memory and learn-
ing, was discovered in the perforant path (Bliss and Lomo, 1973),
and a subsequent study suggests that LTP is induced by acute
nicotine in the medial perforant path of nicotine-primed rats
(Hamid et al., 1997). We tested whether the increased expression
of 4* nAChR and their activation in the medial perforant path
can facilitate LTP induction in mouse horizontal hippocampal
slices (Fig. 7). We conducted experiments with a presynaptic
stimulus intensity (eliciting 40% of the maximum fEPSP slope)
(Fig. 7B) that did not induce LTP in the absence of nicotine. In
slices from chronically nicotine-treated (2 mg  kg1  h1 for
10–14 d) mice, acute nicotine application (1 M for 2 min, three
times) during tetanic stimulation (100 Hz for 1 s, three times)
resulted in robust induction of LTP, because fEPSP slope in-
creased to 131  2% of baseline (Fig. 7C). Little or no LTP was
found with acute nicotine in slices from mice chronically treated
with saline, with slices from both chronic nicotine and chronic
saline-treated mice acutely treated with saline (Fig. 7D), or with
acute application of the noncompetitive antagonist mecamylamine
in slices from mice chronically treated with nicotine (the latter re-
sulted in a slight depressionof the fEPSC) (data not shown).Wealso
found that, when the stimulus strength was increased to a level that
produced 80% of the maximum fEPSP, significant LTP resulted
even in the absence of chronic or acute nicotine exposure (data not
shown). Thus, activation of the upregulated4* nicotinic receptors
by nicotine lowered the stimulus threshold for LTP induction.
4YFP upregulation in other areas
Other brain regions showing upregulation of4YFP fluorescence
with chronic nicotine (2 mg  kg1  h1) included the anterior
cingulate cortex (increase of 36  8%), superior colliculus (in-
crease of 34 12%), and the caudate–putamen (increase of 18
4%) (Tables 1, 2). With chronic nicotine administration, there
Figure 6. Patch recordings from midbrain dopaminergic neurons in slices from mice ex-
posed to chronic nicotine or saline. A, Chronic nicotine treatment decreased the baseline firing
rate of SNC dopaminergic neurons. Typical traces (3 s) and time course of firing also show that
nicotine (1M) bath perfusion increased firing rate in SNC dopaminergic neurons from chronic
saline (empty circles)- andnicotine (filled circles) (a, baseline; b, peak; c,wash)-treatedmice.B,
C, Summary of nicotine-induced increment of firing rate in SNC dopaminergic neurons. Data in
time course and summary are shown as mean SEM.
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was no significant change of 4YFP fluorescence in the dorsolat-
eral geniculate nucleus of the thalamus, the medial habenula, the
fasciculus retroflexus, the nucleus accumbens, or the somatosen-
sory area of the cerebral cortex (Tables 1, 2). Interestingly, there
was a decrease in 4YFP fluorescence in the interpeduncular nu-
cleus (Tables 1, 2).
Discussion
In the strategy of these experiments, (1) we first constructed a
mouse strain with fluorescent 4* receptors. (2) We examined
several brain regions for upregulation of fluorescence in response
to chronic nicotine. (3) In two cell types showing the strongest
upregulation (midbrain GABAergic neurons and axons of the
medial perforant path), we performed appropriate physiology to
verify functionality of the upregulated receptors. (4) In the dopa-
minergic neurons that, unexpectedly, showed no numerical up-
regulation, we confirmed electrophysi-
ologically that there is no functional
upregulation.
The relevance of our study depends
strongly on experiments associated with
step (1). We find that the 4 knock-in
mice are quantitatively normal in all re-
spects studied: the regional and cellular
pattern of fluorescence (Figs. 1, 3–7; sup-
plemental Fig. S5, available at www.
jneurosci.org as supplemental material);
nicotine-induced currents (supplemental
Fig. S2, available at www.jneurosci.org as
supplemental material), Ca2 fluxes (sup-
plemental Fig. S2, available at www.
jneurosci.org as supplemental material),
86Rb effluxes (Fig. 2); GABA and dopa-
mine release (Fig. 2); 125I-epibatidine
binding (Fig. 2); 125I-mAb299 labeling
(Fig. 2); and nicotine-induced antinoci-
ception (supplemental Fig. S3, available at
www.jneurosci.org as supplemental mate-
rial). We also point out the good agree-
ment, at the regional level, between the
present study of upregulated receptors
versus previous studies of upregulated nic-
otine binding. Indeed, for the nine regions
studied with both techniques, the correla-
tion coefficient is 0.91 between percentage
upregulation of fluorescence and the per-
centage upregulation of nicotine binding
(Pauly et al., 1991;Marks et al., 1992). Our
study also confirms that the previous data
on upregulated ligand binding do repre-
sent increases in actual nicotinic receptor
protein.
Although others have previously found
different effects of chronic nicotine among
brain areas, in this study the excellent res-
olution of fluorescence has led to the impor-
tant fact that4 upregulation occurs in only
a subset of 4-expressing neuronal types.
We show here that this cell-specific upregu-
lation provides insights that could resolve
the “upregulation dilemma” for 4-
dependent processes.
Changes in dopaminergic pathways
suggest a mechanism for tolerance
That functional 4* nAChRs are upregulated in GABAergic but
not dopaminergic neurons in midbrain by chronic nicotine can,
in a general sense, provide mechanisms that lead from upregu-
lated, functional receptors to downregulated release of dopamine
(Fig. 8). Our data on GABAergic neurons emphasize cell bodies,
consistent with the observation that increased nAChR receptor
function from upregulation in inhibitory neurons in the mid-
brain leads to a corresponding increased basal firing. Our data on
midbrain dopaminergic neurons also emphasize cell bodies and
lack the resolution to detect possible changes in receptor num-
bers or function at the presynaptic nerve terminals of dopami-
nergic axons. However, chronic nicotine also fails to enhance
nicotinic stimulation of dopamine release from pinched-off
nerve terminals (Grady et al., 1997). Thus, there is little or no
Figure 7. 4YFP in the hippocampus and LTP experiments on the medial perforant path. A, A montage of tiled spectral
confocal images of the hippocampus from a Hom 4YFP mouse, showing strong 4YFP fluorescence in axonal fiber tracts
including themedial perforant path, the temperoammonic path, and the alveus. Py, Pyramidal cell layer; Or, stratum oriens; Rad,
stratum radiatum; L Mol, stratum lacunosummolecular. B, An input– output relationship for fEPSP response slopes. The bottom
inset shows the traces with varying stimulus intensities. The stimulus intensity eliciting 40% of the maximal slope was used for
baseline stimulus and LTP induction. The top inset shows a paired-pulse stimulation with 50 ms interstimulus interval. The
paired-pulse inhibition confirms that stimulation and recording were done in the medial perforant path. C, Traces and plots are
shown for fEPSP slope responses on LTP induction recorded from the medial perforant path in hippocampal slices from mice
chronically treated with saline or nicotine (2 mg  kg1  h1 for 10–14 d). Note that fEPSP waveforms are an average of 10
traces. Slices receiving acute nicotine (1M) and tetanic stimuli in chronic nicotine-treated mice had larger LTP induction than
chronic saline-treatedmice.D, Traces and plots of fEPSP slope responses inmedial perforant path in hippocampal slices frommice
receiving either chronic saline or chronic nicotine. With tetanic stimuli and acute saline, there was no induction of LTP from slices
in both chronic saline- and chronic nicotine-treated mice.
Nashmi et al. •4* Receptors in Glutamatergic and GABAergic Neurons J. Neurosci., August 1, 2007 • 27(31):8202–8218 • 8213
evidence that chronic nicotine upregulates
the number or function of highly nicotine-
sensitive receptors in dopaminergic
neurons.
Although it will probably take some
time before all details are known, we pro-
vide two exemplary suggestions that use
both the present data and the known facts
about ventral midbrain circuitry. The first
example explains contemporary data on
altered accumbal dopamine release in rats
recently withdrawn from chronic nicotine
(Rahman et al., 2004) (Fig. 8B,C) (Nisell
et al., 1997; Cadoni and Di Chiara, 2000).
(1) Endogenous acetylcholine, released
from synaptic terminals of cholinergicme-
sopontine neurons, activates the upregu-
lated receptors, increasing GABAergic
neuron firing. This accounts for the data of
Figure 5,A andB. The increased inhibitory
firing decreases the firing of the dopami-
nergic target neurons. This accounts for
the data of Figure 6, A and B, providing a
mechanism for dysphoria in the absence of
nicotine. (2) During acute nicotine intake,
the upregulated receptors increase excita-
tion of the GABAergic neurons; this ex-
plains the data of Figure 5, A and C. This
increased firing further inhibits the dopa-
minergic neurons, partially counteracting
their direct excitation by nicotine; this ac-
counts for the data of Figure 6, A and C.
Tolerance to chronic nicotine thus could
arise from cell-specific upregulation com-
bined with the sign-inverting properties of
a pathway that includes inhibitory
neurons.
Another study in rodents showed that
chronic nicotine decreased brain reward
function as measured by increased thresh-
old of intracranial self-stimulation
(Epping-Jordan et al., 1998). The circuits
are probably complicated by interneuro-
nal inhibition of GABAergic neurons (Ste-
ffensen et al., 1998) and by electrical cou-
pling of GABAergic interneurons (Stobbs
et al., 2004). Although other data on mid-
brain cultures show that chronic nicotine
upregulates functional4* receptors on all
the GABAergic neurons (Nashmi et al.,
2003; Tapper et al., 2004; Nashmi and
Lester, 2007), we caution that the present
slice electrophysiology data derive only
from substantia nigra recordings.
A conclusion of our study is that up-
regulation of functional receptors on in-
hibitory neurons, not desensitization, can
explain functional tolerance to nicotine.
This view is consistent with a remaining
role for desensitization in some aspects of the acute response to
nicotine (Mansvelder et al., 2002). In fact, because desensitiza-
tion occurs with a high probability after channel opening, up-
regulationmay arisemore strongly from the desensitized than the
activated state of receptors. Conversely, we cannot rule out the
idea that each upregulated receptor molecule also features a sub-
tly enhanced functional response to agonists (Vallejo et al., 2005).
We donot yet knowwhether upregulation of4* receptors on
Figure 8. Possible consequences of upregulated functional4 receptors onmidbrain GABAergic neurons.A, Simplified circuit
diagram showing the cholinergic lateral tegmental nucleus (LDT) projecting to VTA, in which10% of neurons are GABAergic
neurons and inhibit the dopaminergic neurons. Both GABAergic and dopaminergic neurons express 4* receptors. The VTA
dopaminergic neurons projectmainly to the nucleus accumbens.B, C, Events in the nicotine-naive and upregulated VTA, explain-
ing contemporary data from animals yoked to other animals that self-administer nicotine (C) (Rahman et al., 2004). In a nicotine-
naive animal, endogenous AChmodestly excites GABAergic neurons; and first exposure to nicotine robustly activates dopaminer-
gic neurons (“Yoked saline” in C). After chronic nicotine (“Yoked nicotine” in C), endogenous ACh provides increased inhibitory
tone caused by increased4* receptors in GABAergic neurons. This leads to decreased basal dopamine release, asmeasured in C.
Then, a nicotinedose activates theGABAergic neuronsmore thanpreviously, blunting activationof thedopaminergic neurons and
dopamine release, as measured in C. D, The pedunculopontine tegmental nucleus (PPTg) provides the major cholinergic projec-
tion to SN. In SN, the GABAergic and dopaminergic neurons aremostly segregated into SNR and SNC, respectively. As in VTA, both
cell typeshave4* receptors. SNRneuronshave important inhibitoryprojections to SNC (Mailly et al., 2003) aswell as to thalamus
and other regions. The events pictured in B and Cwould also apply to SNC.
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GABAergic neurons is a general phenomenon that extends out-
sidemidbrain; but data from hippocampal interneurons (Alkon-
don and Albuquerque, 2005) and from GABAergic striatal syn-
apses (Miura et al., 2006) provide additional examples. The
present data are not informative with respect to hippocampal
interneurons, because we found few if any hippocampal inter-
neurons that express the 4 fluorescence (Fig. 7), as expected
from themixed C57BL/6/129SvJ background of ourmice (Gahr-
ing et al., 2004).
Possible mechanisms in substantia nigra
In part because we wanted to maintain unambiguous identifica-
tion of dopaminergic and GABAergic neurons, our slice record-
ings used substantia nigra, which participates in both reward and
the control of movement (Stolerman and Shoaib, 1991; Mire-
nowicz and Schultz, 1996; Schultz et al., 1998). These results
provide our second suggestion that upregulated functional 4*
nAChRs could lead to altered dopaminergic function. In substan-
tia nigra of a chronically treated intact animal (Fig. 8D), endog-
enous ACh would also increase (Fig. 5) or regularize SNR
GABAergic neuron firing, similar to the suggested benefits of
subthalamic nucleus stimulation (Garcia et al., 2005). Via direct
SNR to SNC projections (Tepper et al., 1995; Mailly et al., 2003),
regularized SNR firing would also decrease firing in SNC dopa-
minergic neurons (Fig. 6), or specifically decrease burst firing in
SNC neurons. This change could protect SNC neurons from ex-
cessive activation during any of the several inherited or acquired
metabolic conditions that tend to depolarize dopaminergic neu-
rons. In support of this suggested role for 4* receptors, 4 KO
mice are less susceptible than WT to protection by nicotine in
toxin-induced SN dopaminergic degeneration (Ryan et al.,
2001). Such protection provides possible mechanisms for the in-
verse correlation between smoking andParkinson’s disease (Tan-
ner et al., 2002; Scott et al., 2005; Wirdefeldt et al., 2005).
Sensitization to nicotine at glutamatergic synapses suggests a
mechanism for cognitive enhancement
We observed that chronic exposure to nicotine robustly in-
creased 4 fluorescence in the perforant path. In slices from
chronically nicotine-treated (but not saline-treated) mice, we
then found that acute exposure to nicotine during tetanic stimuli
enhances induction of long-term potentiation in the medial per-
forant path (Fig. 7). Our data on these neocortical glutamatergic
neurons emphasize axons, where 4* receptor upregulation pre-
sumably arises from enhanced assembly in the soma (Nashmi et
al., 2003). Nicotinic activation in axons may result either in in-
creased firing rates or in increased Ca2 influx near presynaptic
terminals (MacDermott et al., 1999; Lambe et al., 2003). In this
example of nicotine-dependent plasticity, the effect of chronic
nicotine thus appears directly explainable by action at a single
synapse.
To the extent that LTP of perforant path–dentate gyrus syn-
apses provides an admittedly oversimplified model for some as-
pects of cognition, nicotine-induced upregulation of 4* recep-
tors in glutamatergic presynaptic structures appears to be a
mechanismworth additional investigation in cognitive sensitiza-
tion by nicotine. These data provide a plausible parallel to reports
that, 24 h after withdrawal from nicotine, mice given acute nico-
tine perform better in a hippocampal-dependent task (Davis et
al., 2005) and that chronic nicotine improves spatial working
memory in the radial arm maze (Levin et al., 1990, 1996). In the
CA1 andCA3 subfield of the hippocampus, chronic nicotinemay
act via more complex circuit changes (Fujii et al., 1999; Fujii and
Sumikawa, 2001; Yamazaki et al., 2006a; Nakauchi et al., 2007).
Chronic nicotine also produced increases in 4YFP fluores-
cence, presumably in glutamatergic neurons, in the anterior cin-
gulate cortex (increase of 36%), another neocortical region in-
volved in cognition. We also find nicotine-induced upregulation
in superior colliculus (increase of 34%), a midbrain nucleus.
However, the glutamatergic neurons of themajor thalamic nuclei
showed no upregulation, in agreement with previous functional
data (Nguyen et al., 2004). Chronic exposure to nicotine upregu-
lates functional 4* nAChRs in some but not all glutamatergic
neurons.
Mechanism of cell-specific upregulation of 4* receptors
In previous studies on cultured midbrain neurons from WT
mice, chronic nicotine upregulated both 4* functional re-
sponses and4* protein levels (Nashmi et al., 2003; Tapper et al.,
2004). We also find that upregulation occurs in homotypic
GABAergic cultures lacking their typical presynaptic partners
and when tested with ACh concentrations that activate only the
4 receptors (Nashmi and Lester, 2007).
Upregulation may arise primarily because more nicotinic re-
ceptors are assembled or stabilized in an easily activated state
(Nashmi et al., 2003; Darsow et al., 2005; Kuryatov et al., 2005;
Sallette et al., 2005; Vallejo et al., 2005). Upregulation of 42*
receptors appears to depend on specific regions of sequence in the
4 and 2 subunits (Sallette et al., 2004), possibly because these
regions allow nicotine to act as a “pharmacological chaperone”
(Kuryatov et al., 2005; Sallette et al., 2005). Other data suggest
that upregulated receptors have altered functional states, with
slower desensitization and enhanced sensitivity to low agonist
concentrations (Sallette et al., 2005; Vallejo et al., 2005). There-
fore, the cell type-specific upregulation that we observemay itself
arise from differences in subunit composition: dopaminergic
neurons, but neither GABAergic nor glutamatergic neurons, in-
corporate 6 subunits into some or all 4* nAChRs (Champ-
tiaux et al., 2003; Salminen et al., 2004; Gotti et al., 2005); and6*
receptors are relatively insensitive to upregulation (Klink et al.,
2001; Tumkosit et al., 2006). Cell-specific upregulation could
also arise from proteins that govern assembly and trafficking
(Keller et al., 2001;Marchand et al., 2002; Darsow et al., 2005; Liu
et al., 2005; Sallette et al., 2005;Vallejo et al., 2005; Xu et al., 2006),
from mechanisms that regulate receptor turnover (Kuryatov et
al., 2005), or from additional factors that regulate desensitization
(Mansvelder et al., 2002).
Conclusions
The data meet the challenge presented in Introduction: to find
cell types in which 4* receptors are upregulated by chronic nic-
otine; to test the upregulated receptors for functionality; and to
suggest how upregulated, functional receptors can explain two
separate effects of chronic nicotine: forebrain-dependent sensiti-
zation and midbrain-dependent tolerance. A complete patho-
physiological explanation for nicotine addiction must account
for several other phenomena such as withdrawal (Koob et al.,
2004; Laviolette and van derKooy, 2004); nor dowe claim to have
discovered the complete mechanism for the inverse correlation
between smoking and Parkinson’s disease (Tanner et al., 2002;
Scott et al., 2005; Wirdefeldt et al., 2005). Furthermore, our data
do not provide a role for reported nicotine-induced adaptations
in proteins other than nAChRs (Chang and Berg, 2001; Ferrari et
al., 2002; Brunzell et al., 2003; Marrero et al., 2004; Yeom et al.,
2005; Marttila et al., 2006; Yamazaki et al., 2006b; Fornari et al.,
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2007). Additional nAChR subtypes presumably also play a role in
responses to chronic nicotine; perhaps these roles could be inves-
tigated in knock-in mice expressing the appropriate fluorescent
receptor subunits.
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